Search for: "Sigma-Aldrich, Inc."
Results 1 - 10
of 10
Sorted by Relevance
|
Sort by Date
19 Feb 2008, 9:45 pm
Sigma Aldrich, Inc., and the claim related to the drug. [read post]
10 Jan 2023, 8:18 pm
And while the various CRISPR interferences between The Broad Institute and the University of California (Nos. 105,048 and 105,115) and those parties and ToolGen (Nos. 106,126 and 106,127) and Sigma-Aldrich (Nos. 106,132 and 106,133) have... [read post]
31 Oct 2012, 10:31 am
Corning will supply the items to Sigma-Aldrich to market under Sigma-Aldrich's own brand until the company is able to make them itself - an arrangement that will "immediately replace the competition lost as a result of Corning's acquisition of Discovery Labware," according to the FTC. [read post]
6 Jul 2020, 3:12 am
Sigma-Aldrich, not Merck gave misleading info in deal review, EU says. [read post]
26 Feb 2010, 4:17 pm
Sigma-Aldrich Corporation; Seirus Innovative Accessories, Inc. v. [read post]
26 Jul 2017, 3:22 pm
’” And its brief notes that patent examiners rejected similar eukaryotic cell CRISPR patent applications from Sigma-Aldrich and ToolGen—filed before the Broad’s patent application—because it made claims that were “non-novel” or obvious in light of UC’s disclosed work.Jacob Sherkow, an intellectual property attorney at the New York Law School in New York City who has closely followed each round in the fierce battle, says the UC… [read post]
25 Jan 2010, 5:00 am
See Basic, Inc. v. [read post]
19 Sep 2013, 9:53 am
Pfizer, Inc., 712 F.3d 21 (1st Cir. 2013), Aetna, Inc. v. [read post]
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited relating to repackaging and de-branding of… [read post]
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US: Survey shows most Americans… [read post]
